Cathepsin B Degrades Amyloid-β in Mice Expressing Wild-type Human Amyloid Precursor Protein
Open Access
- 1 November 2012
- journal article
- research article
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 287 (47), 39834-39841
- https://doi.org/10.1074/jbc.m112.371641
Abstract
Accumulation of amyloid-β (Aβ), believed to be a key trigger of Alzheimer disease (AD), could result from impaired clearance mechanisms. Previously, we showed that the cysteine protease cathepsin B (CatB) degrades Aβ, most likely by C-terminal truncation, in mice expressing human amyloid precursor protein with familial AD-linked mutations (hAPPFAD). In addition, the Aβ-degrading activity of CatB is inhibited by its endogenous inhibitor, cystatin C (CysC). Reducing CysC expression markedly lowers Aβ levels by enhancing CatB-mediated Aβ degradation in hAPPFAD mice. However, because a vast majority of AD patients do not carry familial mutations, we investigated how the CysC-CatB axis affects Aβ levels in mice expressing wild-type hAPP (hAPPWT). Enhancing CatB activity by CysC deletion significantly lowered total Aβ and Aβ42 levels in hAPPWT mice, whereas CatB deletion increased Aβ levels. To determine whether neuron-derived CatB degrades Aβ in vivo, we generated transgenic mice overexpressing CatB under the control of a neuron-specific enolase promoter. Enhancing neuronal CatB activity in hAPPWT mice significantly lowered Aβ42 levels. The processing of hAPPWT was unaffected by increasing or ablating CatB activity. Thus, the CysC-CatB axis affects degradation of Aβ42 derived from hAPP lacking familial mutations. These findings support the notion that enhancing CatB activity could lower Aβ, especially Aβ42, in AD patients with or without familial mutations.Keywords
This publication has 33 references indexed in Scilit:
- Nonpeptidic Lysosomal Modulators Derived from Z-Phe-Ala-Diazomethylketone for Treating Protein Accumulation DiseasesACS Medicinal Chemistry Letters, 2012
- Genetic cathepsin B deficiency reduces β-amyloid in transgenic mice expressing human wild-type amyloid precursor proteinBiochemical and Biophysical Research Communications, 2009
- Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in SituJournal of Biological Chemistry, 2006
- Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2000
- High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque FormationJournal of Neuroscience, 2000
- Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor geneMolecular Pathology, 1999
- Interaction of Cystatin C Variants with Papain and Human Cathepsins B, H and LJournal of Enzyme Inhibition, 1999
- Increased Neuronal Endocytosis and Protease Delivery to Early Endosomes in Sporadic Alzheimer’s Disease: Neuropathologic Evidence for a Mechanism of Increased β-AmyloidogenesisJournal of Neuroscience, 1997
- Amyloid precursor protein processing and Aβ 42 deposition in a transgenic mouse model of Alzheimer diseaseProceedings of the National Academy of Sciences of the United States of America, 1997
- Amyloid ?/A4 Precursor Protein (APP) Processing in LysosomesAnnals of the New York Academy of Sciences, 1992